201. Advanced glycation end products/peptides: an in vivo investigation
- Author
-
Annunziata Lapolla, Giordano Pastori, R. Reitano, Luciana Bonfante, Pietro Traldi, Michela Tubaro, Domenico Fedele, and Roberta Seraglia
- Subjects
Glycation End Products, Advanced ,Nephrotic Syndrome ,Electrospray ionization ,Peptide ,Mass spectrometry ,General Biochemistry, Genetics and Molecular Biology ,Mass Spectrometry ,End stage renal disease ,symbols.namesake ,History and Philosophy of Science ,Glycation ,In vivo ,Reference Values ,Diabetes mellitus ,medicine ,Diabetes Mellitus ,Humans ,Amines ,Serum Albumin ,chemistry.chemical_classification ,General Neuroscience ,Serum Albumin, Bovine ,medicine.disease ,Peptide Fragments ,Maillard Reaction ,Maillard reaction ,Glucose ,Biochemistry ,chemistry ,symbols - Abstract
Advanced glycation end products/peptides (AGE/peptides) originate by in vivo enzymatic digestion of nonenzymatically glycated proteins, which are produced by reaction of glucose with primary amino groups present in the protein chain following the Maillard pattern. AGE/peptides are highly reactive species and can interact with tissue and circulating proteins, leading to tissue modification and impaired protein functionality. Serum levels of AGE/peptides are reported to be particularly high in diabetes (in terms of higher production) or in end-stage renal disease (in terms of accumulation). For these reasons, their structural identification is of high interest, giving information on their relationship with the pathological state and allowing the design of possible therapeutic interventions. We report here some preliminary results obtained by liquid chromatography/electrospray ionization/mass spectrometry (LC/ESI/MS) and matrix-assisted laser desorption ionization MS (MALDI-MS) investigations carried out on the low-molecular-weight serum peptide fraction from 10 healthy subjects, 10 patients with poorly controlled diabetes, and 10 patients with end-stage nephropathy.
- Published
- 2005